|国家科技期刊平台
首页|期刊导航|中国实用儿科杂志|《欧洲儿科胃肠病学、肝病学和营养学学会关于益生菌治疗儿童胃肠道疾病的立场文件》解读

《欧洲儿科胃肠病学、肝病学和营养学学会关于益生菌治疗儿童胃肠道疾病的立场文件》解读OA北大核心CSTPCD

Interpretation of Probiotics for the Management of Pediatric Gastrointestinal Disorders:Position Paper of ESPGHAN

中文摘要英文摘要

肠道菌群对人类健康有着不可忽视的关键性作用,而益生菌是靶向肠道菌群重要且有效的干预手段之一.欧洲儿科胃肠病学、肝病学和营养学学会(ESPGHAN)益生菌和益生元工作组近年来发布了若干份关于使用益生菌预防或治疗儿童胃肠道疾病的临床指南.而2022版ESPGHAN关于益生菌治疗儿童胃肠道疾病的立场文件对早期指南中所包含的适应证进行了更新及补充,针对儿童胃肠道疾病使用益生菌提供了最全面的应用建议.该文在对文件进行解读的基础上,结合中国实际情况,以期指导医生进行临床决策.

The gut microbiome plays a critical role in human health,and probiotics are one of the important and effective interventions targeting the gut microbiome.In recent years,the European Society for Paediatric Gastroenterology,Hepatology and Nutrition(ESPGHAN)Working Group published several clinical guidelines on the use of probiotics for preventing or treating gastrointestinal disorders in children.The 2022 edition of the ESPGHAN Position Paper on Probiotics for the Management of Pediatric Gastrointestinal Disorders updates and complements the indications contained in the earlier guidelines,providing the most comprehensive recommendations for the use of probiotics in pediatric gastrointestinal disorders.On the basis of the interpretation of this position paper,this article takes the situationin China into consideration,with a view to guiding pediatricians in their clinical decision-making.

吕垚;甄长君;陈洁

浙江大学医学院附属儿童医院消化内科 国家儿童健康与疾病临床医学研究中心,浙江杭州 310052

临床医学

益生菌胃肠道疾病儿童立场文件

probioticsgastrointestinal disorderchildposition papers

《中国实用儿科杂志》 2024 (008)

561-566 / 6

浙江省自然科学基金(LQ22H160006)

10.19538/j.ek2024080601

评论